Zobrazeno 1 - 10
of 249
pro vyhledávání: '"Mark Genovese"'
Autor:
Sam Lim, Matthew Baker, Vimal Derebail, Yashaar Chaichian, Mark Genovese, Panduranga Rao, Winn Chatham, Michael Bubb, Hooman Hajian, Oksana Gurtovaya, Uptal Patel, James Tumlin
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objectives Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking. This trial assessed the pre
Externí odkaz:
https://doaj.org/article/c9f79c28f9ee49ac9315662dd767f3a8
Autor:
Mark Genovese, Rene Westhovens, Luc Meuleners, Annegret Van der Aa, Pille Harrison, Chantal Tasset, Arthur Kavanaugh
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Abstract Background The aim was to assess patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib during two phase 2b, 24-week, randomized, placebo-controlled studies. Methods Patients with moderate-to-seve
Externí odkaz:
https://doaj.org/article/ed6c8f8a21764ebbbcd4ac04948395eb
Autor:
Gilead Sciences, Inc.
Publikováno v:
Business Wire (English). 06/01/2020.
Autor:
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro, Eiji Sugiyama, Kunihiro Yamaoka, Bernard G Combe, Alan J Kivitz, Sang-Cheol Bae, Edward C Keystone, Peter Nash, Mark Genovese, Franziska Matzkies, Beatrix Bartok, Alena Pechonkina, Akira Kondo, Lei Ye, Qi Gong, Chantal Tasset, Tsutomu Takeuchi
Publikováno v:
Modern Rheumatology.
Objectives To present safety and efficacy of the JAK1 preferential inhibitor filgotinib in Japanese patients with prior inadequate response (IR) to methotrexate (MTX) from a 52-week randomised controlled parent study (PS) and long-term extension (LTE
Autor:
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark Genovese, Khalid Ahmed, Jeffrey Alper, Nichol Barkham, Ralph E. Bennett, Francisco Javier Blanco García, Ricardo Blanco Alonso, Howard B. Blumstein, Michael S. Brooks, Gerd-Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der-Yuan Chen, Melvin A. Churchill, Christine E. Codding, Peter M.G. Deane, Jose Del Giudice, Atul A. Deodhar, Rajat K. Dhar, Eva Dokoupilova, Rita M. Egan, Andrea Everding, Eva Galíndez, David H. Goddard, Alice Gottlieb, Philippe Goupille, Robert M. Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu-Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan J. Kivitz, Steven J. Klein, Mariusz P. Korkosz, Roshan Kotha, Joel M. Kremer, Cummins Lue, José Luis Marenco de la Fuente, Helena Marzo-Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama C. Nandagudi, Antonio Fernández-Nebro, Clark M. Neuwelt, Ana Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria E. Rell-Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David H. Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen-Fang Tsai, Anthony M. Turkiewicz, Leonore Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielinska
Publikováno v:
Lancet (London, England). 389(10086)
Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment refractory to subsequent therapeutic interventions than previously untreated patients. We report the efficacy
Autor:
Jinoos, Yazdany, Mark, Robbins, Gabriela, Schmajuk, Sonali, Desai, Diane, Lacaille, Tuhina, Neogi, Jasvinder A, Singh, Mark, Genovese, Rachel, Myslinski, Natalie, Fisk, Melissa, Francisco, Eric, Newman
Publikováno v:
Arthritis careresearch. 68(11)
Electronic clinical quality measures (eCQMs) rely on computer algorithms to extract data from electronic health records (EHRs). On behalf of the American College of Rheumatology (ACR), we sought to develop and test eCQMs for rheumatoid arthritis (RA)
Publikováno v:
Eli Lilly & Company MarketLine Company Profile. 9/6/2024, p1-58. 58p.
Autor:
Mark, Genovese
Publikováno v:
New Jersey nurse. 34(2)
Autor:
Ting, Ma, Keita, Miyanishi, Michael C D, Trindade, Mark, Genovese, Donald, Regula, R Lane, Smith, Stuart B, Goodman
Publikováno v:
The Journal of rheumatology. 30(12)
To test the in vivo effects of interleukin 1 receptor antagonist (IL-1ra) on bone formation and tissue ingrowth using an implantable bone ingrowth chamber that can be infused with test solutions.The bone ingrowth chamber was implanted in the proximal
Autor:
Arthur, Kavanaugh, Mark, Genovese, Jan, Baughman, Alan, Kivitz, Ken, Bulpitt, Nancy, Olsen, Michael, Weisman, Eric, Matteson, Daniel, Furst, Ronald, van Vollenhoven, James, Anderson, Stanley, Cohen, Nathan, Wei, Jan, Meijerink, Cindy, Jacobs, Simonetta, Mocci
Publikováno v:
The Journal of rheumatology. 30(3)
Human cartilage glycoprotein 39 (HC gp-39) appears to be a relevant autoantigen in patients with rheumatoid arthritis (RA). Administration of major histocompatibility complex (MHC) Class II complexed antigens without requisite costimulatory signals c